Shaalan Beg MD MBA FASCO retweeted
Great perspective from @PauloBergerot in @ASCO Daily News on a critical challenge in #ExerciseOncology: moving beyond the optimal exercise dose to interventions that are feasible, accessible, and sustainable in patients’ everyday lives #ASCOQLTY26
dailynews.ascopubs.org/do/can-exercis…
dailynews.ascopubs.org/do/can-exercis…
2
9
32
2,681
Shaalan Beg MD MBA FASCO retweeted
Our atlas of young-onset CRC is finally out in @NatureMedicine! We found a unique biology in younger patients that may explain the aggressive nature of this disease. This was a monumental effort with colleagues at @MassGenBrigham and @broadinstitute. @DFarberYoungCRC
Researchers co-led by @KimmieNgMD of @DanaFarber and @DFarberYoungCRC created the largest single-cell atlas of colorectal cancer ever, identifying age-associated differences that may help research into why #colorectalcancer can be more aggressive in younger adults. qO
8
43
171
15,001
Shaalan Beg MD MBA FASCO retweeted
ASCO Members! You now get full access to ASCO Meetings content 30 days post-meeting. Explore the latest science faster! View content from the 2026 ASCO Annual Meeting: bit.ly/4hXg1DS
Coming soon: An AI-powered agent from ASCO & Google Cloud to simplify your research.
Coming soon: An AI-powered agent from ASCO & Google Cloud to simplify your research.
0
4
6
1,669
Shaalan Beg MD MBA FASCO retweeted
We are looking to hire post-doctoral fellows to work on somatic mosaicism, regeneration, and cancer development, please reach out to me if you are interested! @CRI_UTSW
0
14
18
3,753
Shaalan Beg MD MBA FASCO retweeted
Dr. @QasimHussainiMD giving an amazing discussion of two studies on #ExerciseOncology presented at @ASCO Quality Care Symposium this morning.
asco.org/quality/program
#ASCOQLTY26 @crisbergerot @PauloBergerot
asco.org/quality/program
#ASCOQLTY26 @crisbergerot @PauloBergerot
0
11
19
1,567
Shaalan Beg MD MBA FASCO retweeted
Fantastic oral abstract discussion by Dr. @CharlesJiangMD at @ASCO Quality Care Symposium today!
asco.org/quality/progra…
#ASCOQLTY26 @utswcancer @UTSWMedCenter
asco.org/quality/progra…
#ASCOQLTY26 @utswcancer @UTSWMedCenter
1
5
20
1,056
Hey, @TimothyJBrownMD, can an F-150 do this?
Tesla unveiled a redesigned Roadster equipped with thrusters that enable it to fly short distances, nearly nine years after it first showed a next-generation version of its electric sports car, and said it would start production in 2028 reut.rs/4zt7Q9A
1
0
1
1,503
Shaalan Beg MD MBA FASCO retweeted
Great to see work from @ASCO Quality Care Symposium simultaneously published in @JCO_ASCO today:
“Effectiveness of a Multisite Oncology Financial Navigation Intervention: The Lessening the Impact of Financial Toxicity Clinical Trial.”
ascopubs.org/doi/pdf/10.120…
#ASCOQLTY26
“Effectiveness of a Multisite Oncology Financial Navigation Intervention: The Lessening the Impact of Financial Toxicity Clinical Trial.”
ascopubs.org/doi/pdf/10.120…
#ASCOQLTY26
1
8
21
886
Geographical access to clinical trials remains the number one barrier to enrollment.
Look forward to hearing how technology-enabled services are being used by sites to improve access to cancer trials. #ascoqlty26
Look forward to hearing how technology-enabled services are being used by sites to improve access to cancer trials. #ascoqlty26
Growing excitement for the @ASCO Quality Care Symposium (#ASCOQLTY26) this week!
Nice overview of one of the studies on Decentralizing Clinical Trials being presented at the meeting:
dailynews.ascopubs.org/do/decentraliz…
@JamesFanWu @crisbergerot @ShaalanBeg
#CancerResearch #ClinicalTrials
1
1
5
625
Shaalan Beg MD MBA FASCO retweeted
Atezolizumab is now @FDA ✅ off #ATOMIC Ph III, adj mFOLFOX + Atezo vs. mFOLFOX in Stg III dMMR colon ca.
- 3yr DFS 86.4% vs 76.6% (HR 0.50)
- OS not mature
- ⬆️ Gr4 neutropenia with Atezo.
- How much is chemo benefitting? Role of NICHE2?
- @ASCO Plenary!
#gism #OncTwitter
- 3yr DFS 86.4% vs 76.6% (HR 0.50)
- OS not mature
- ⬆️ Gr4 neutropenia with Atezo.
- How much is chemo benefitting? Role of NICHE2?
- @ASCO Plenary!
#gism #OncTwitter
2
19
36
3,080
Shaalan Beg MD MBA FASCO retweeted
How has teamwork transformed patient outcomes in your practice? Bring Dr. Elizabeth Mittendorf’s @ASCOPres theme—Intentional Teams. Exceptional Care.—to life on the #ASCO27 stage during the ASCO Voices session.
🎙️ Submit your audition by November 13: bit.ly/4ALUHts
🎙️ Submit your audition by November 13: bit.ly/4ALUHts
1
7
15
4,510
Shaalan Beg MD MBA FASCO retweeted
Based off HER2CLIMB-05, Tucatinib is now @FDA ✅ as maintenance for HER2+ mBC, PhIII, THP —> HP +/-Tucatinib
- Improved PFS in all subsets
- mPFS: 24.9mos vs. 16.3mos (HR: 0.64)
- ⬆️ AEs with Tucatinib (LFTs & diarrhea)
#BreastCancer #bcsm #OncTwitter
- Improved PFS in all subsets
- mPFS: 24.9mos vs. 16.3mos (HR: 0.64)
- ⬆️ AEs with Tucatinib (LFTs & diarrhea)
#BreastCancer #bcsm #OncTwitter
4
21
39
8,222
Shaalan Beg MD MBA FASCO retweeted
We have 3 Anti-Her2 options today for Upper GI adenocarcinoma. Here is the table outlining dose, common toxicities, and clinical pearls in managing these AEs that we touched on during our #ToxCheck discussion with @ShrutiPatelMD & @Sam_Cytryn
#MedTwitter #MedX #OncTwitter
#MedTwitter #MedX #OncTwitter
Tox-Check: Anti-Her2 drugs in Upper GI (Esophageal, GE Junction, and Gastric Adenocarcinoma) w/ @ShrutiPatelMD & @Sam_Cytryn
✅ Trastuzumab
✅ Zanidatamab
✅ TDXd
Full 🗣️:
⭐️ oncbrothers.com/toxcheck-her2-…
⭐️ “Oncology Brothers” podcast
#OncTwitter @OncoAlert @OncUpdates #gism
1
10
34
4,066
Shaalan Beg MD MBA FASCO retweeted
Getting ready to present the phase II GRECO-2 trial Tuesday at #ASTRO26. Can’t stop thinking of you, @TaniguchiMD. There is no way I can represent the purple hair like you did, but I’ll do my best to represent the SOD story.
Missing you, brother. RIP.
Missing you, brother. RIP.
1
7
63
5,640
Shaalan Beg MD MBA FASCO retweeted
⭐️🚨Just published 👉🏼Pleased to share our standout new review 👉🏼published in @TheLancet @eClinicalMed 👉🏼led by 3 amazing rising stars ⭐️ @JiaJennyLiu @niamhjcoleman @JulianaRBeal
👉🏼“Tumour‑agnostic immunotherapy: aligning biological rationale, biomarker precision, and on.”
👉🏼 Tumour‑agnostic immunotherapy has reshaped precision oncology by showing that, in selected settings, treatment benefit can be driven by a shared biological state rather than anatomical origin. The clearest example: MSI‑H/dMMR cancers, where durable responses span diverse malignancies.
⭐️Such a delight to work with & mentor this dream team 👉🏼their clarity, rigor, and vision shine through every section 🎯🔥
@OncoAlert @oncodaily @OncBrothers
thelancet.com/journals/eclin…
👉🏼“Tumour‑agnostic immunotherapy: aligning biological rationale, biomarker precision, and on.”
👉🏼 Tumour‑agnostic immunotherapy has reshaped precision oncology by showing that, in selected settings, treatment benefit can be driven by a shared biological state rather than anatomical origin. The clearest example: MSI‑H/dMMR cancers, where durable responses span diverse malignancies.
⭐️Such a delight to work with & mentor this dream team 👉🏼their clarity, rigor, and vision shine through every section 🎯🔥
@OncoAlert @oncodaily @OncBrothers
thelancet.com/journals/eclin…
4
21
52
2,876
Shaalan Beg MD MBA FASCO retweeted
🚨Another big win for #precisionmedicine
🚨👉🏼Today the FDA approved lirafugratinib for FGFR2‑rearranged cholangiocarcinoma.
⭐️I still remember the first patient in the universe we enrolled on the trial during the peak of the pandemic. Three days in - I called the amazing Ben- Tx
“Your drug is working, working too good. We need to work on the right dosing & get it right for patients. I think this baby will graduate someday.” That day is today 🙌🏼 Thankful to all patients who volunteered & the amazing teams that got this to finish line 🙏🏽 !!! @OncoAlert @oncodaily @OncBrothers @ElizSMcKenna @matthewherper @curecc @Aiims1742 @MiteshBorad @AliSchram
👉🏼Link to FDA approval fda.gov/drugs/resource…
👉🏼Link to @CD_AACR @AACR bench to bedside publication aacrjournals.org/cancerdiscover…
🚨👉🏼Today the FDA approved lirafugratinib for FGFR2‑rearranged cholangiocarcinoma.
⭐️I still remember the first patient in the universe we enrolled on the trial during the peak of the pandemic. Three days in - I called the amazing Ben- Tx
“Your drug is working, working too good. We need to work on the right dosing & get it right for patients. I think this baby will graduate someday.” That day is today 🙌🏼 Thankful to all patients who volunteered & the amazing teams that got this to finish line 🙏🏽 !!! @OncoAlert @oncodaily @OncBrothers @ElizSMcKenna @matthewherper @curecc @Aiims1742 @MiteshBorad @AliSchram
👉🏼Link to FDA approval fda.gov/drugs/resource…
👉🏼Link to @CD_AACR @AACR bench to bedside publication aacrjournals.org/cancerdiscover…
📣Super thrilled to share our paper on RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations & Resistance Mutations, published in @CD_AACR !
👉🏼Huge thanks to team at Cancer Discovery & @AACR fo@AACRing the front page & the entire paper so visually appicine 🧬🎯#cancerresearch @OncoAlert @ElizSMcKenna @Relay_Tx
@TaliLev123
👉🏼Free Link: tinyurl.com/yfffae53
2
27
62
8,334
We are witnessing the most exciting period of drug development in oncology.
There's a lot of discussion on the FDA's Accelerated Approval pathway.
Who should be eligible to receive AA?
When should approvals be withdrawn?
We tackle this #onlyoncologistsinthebuilding 🔎🔎🕵🏻♂️
There's a lot of discussion on the FDA's Accelerated Approval pathway.
Who should be eligible to receive AA?
When should approvals be withdrawn?
We tackle this #onlyoncologistsinthebuilding 🔎🔎🕵🏻♂️
2
3
13
702
@VivekSubbiah @cancerassassin1 @ShrutiPatelMD @PatelOncology @VincentRK @pashtoonkasi here's a link to the full episode please watch and subscribe to our channel!
👇🏻👇🏻
youtu.be/NCkbux-txy4?si…
👇🏻👇🏻
youtu.be/NCkbux-txy4?si…
0
1
2
460
Shaalan Beg MD MBA FASCO retweeted
Team we are SO CLOSE!!! Let’s get this done! @ConquerCancerFd @ASCO @VaniamGroup @DeannavanGestel @UAZCancer
7
35
108
21,128
Shaalan Beg MD MBA FASCO retweeted
New PDAC NCCN guidelines published 9/11/26, daraxonrasib updates posted below. No surprise for the category 1 recommendation in the 2L. Also includes options in progressive locally advanced disease, metastatic recurrence, and 1L mgmt of ECOG 2 and ECOG 3 populations.
3
23
53
4,850